2008, a total of 202 pneumococci were isolated. All pneumococci were characterized by serotype and genotype.
In the fi rst year of this study, we identifi ed 3 (3.1%) serotype 6C pneumococci belonging to 3 sequence types (STs): ST65, ST1714, and ST1692 (online Appendix Figure, available from www.cdc.gov/EID/ content/16/1/154-appF.htm). ST1714 and ST 1692 shared a common clonal complex. Only ST 65 was shared between serotype 6C and serotype 6A.
In the second year, we identifi ed 14 (13.6%) serotype 6C pneumococci belonging to 6 STs (online Appendix Figure) . Two of these STs, of the same ST, were from siblings. Three of them (ST1692 [n = 8], ST1714 [n = 2], and ST395 [n = 1]) were members of a common clonal complex with a predicted founder of ST395. Each of the remaining 3 STs (ST398, ST1862, and ST3460) was isolated only once. One serotype 6A isolate of ST1692 was also observed.
No serotype 6C ST65 was observed in the second year. We isolated more serotype 6C pneumococci in year 2 than in year 1 (p<0.01), which was explained mostly by a large increase in ST1692 (p<0.03) (online Appendix Figure) . A recent study by Nunes et al. reported serotype 6C ST1692 within a clonal complex that also included ST395 and ST1714 (4), and we identifi ed the same clonal complex in year 2 of our study.
Our study showed a large increase in ST1692 in serotype 6C pneumococci during the implementation of PCV7 and an increase in serotype 6C. Depending on the extent of crossprotection between vaccine-related serotypes, introduction of conjugate vaccines could induce clearance or emergence of vaccine-related serotypes. This introduction could also contribute to their substitution with novel or existing serotypes that are better adapted to the ecologic niche. However, our data may only be relevant to carried pneumococci and not refl ected in pneumococcal disease epidemiology. Nevertheless, the increase in serotype 6C pneumococci in the United Kingdom, which is supported by a similar observation in the United States (3), highlights the potential for emergence of serotypes not included in the current study and newly developed pneumococcal conjugate vaccines. From July 2008 through December 2008, we continued to monitor antiviral susceptibility of all infl uenza A (H1N1) viruses in our laboratory, using previously described methods (1). Resistance to oseltamivir increased from 16.9% in July to 97.8% in December (Table) . Sequencing of the hemagglutinin ( 
